Tämä sivu käännettiin automaattisesti, eikä käännösten tarkkuutta voida taata. Katso englanninkielinen versio lähdetekstiä varten.

A Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Failed on One Prior Anti-TNF Therapy (RESET)

torstai 6. heinäkuuta 2017 päivittänyt: Hoffmann-La Roche

Rituximab Phase IIIb Open-label, Multi-centre Assessment of Safety and Effectiveness in Patients With RA Following an Inadequate Response to One Prior Anti-TNF Inhibitor (RESET)

This study will evaluate the safety and effectiveness of MabThera (rituximab) in patients with active rheumatoid arthritis who are receiving methotrexate, and who have a previous or current inadequate response to one prior anti-TNF therapy. All patients will receive MabThera 1000 mg as an intravenous infusion on days 1 and 15. After the initial study phase of 24 weeks, eligible patients may receive one re-treatment with MabThera. The anticipated time on study treatment is 48 weeks.

Tutkimuksen yleiskatsaus

Tila

Valmis

Ehdot

Interventio / Hoito

Opintotyyppi

Interventio

Ilmoittautuminen (Todellinen)

120

Vaihe

  • Vaihe 3

Yhteystiedot ja paikat

Tässä osiossa on tutkimuksen suorittajien yhteystiedot ja tiedot siitä, missä tämä tutkimus suoritetaan.

Opiskelupaikat

  • Kanada
    • Alberta
      • Edmonton, Alberta, Kanada, T6G 2B7
      • Edmonton, Alberta, Kanada, T5M 0H4
    • British Columbia
      • Kelowna, British Columbia, Kanada, V1Y 3G8
      • Vancouver, British Columbia, Kanada, V5Z 3Y1
      • Victoria, British Columbia, Kanada, V8V 3P9
    • Manitoba
      • Winnipeg, Manitoba, Kanada, R3A 1M4
    • Newfoundland and Labrador
      • St John's, Newfoundland and Labrador, Kanada, A1A 5E8
      • St John's, Newfoundland and Labrador, Kanada, A1C 5B8
    • Ontario
      • Hamilton, Ontario, Kanada, L8N 1Y2
      • Hamilton, Ontario, Kanada, L8S 4J9
      • Mississauga, Ontario, Kanada, L5M 2V8
      • Nepean, Ontario, Kanada, K2G 6E2
      • Ottawa, Ontario, Kanada, K1H 8L6
      • Ottawa, Ontario, Kanada, K1S 1C2
      • Thunder Bay, Ontario, Kanada, P7B 5G3
      • Toronto, Ontario, Kanada, M4K 1N2
      • Toronto, Ontario, Kanada, M5T 2S8
      • Toronto, Ontario, Kanada, M5G 1X5
      • Windsor, Ontario, Kanada, N8X 5A6
    • Quebec
      • Laval, Quebec, Kanada, H7G 2E6
      • Montreal, Quebec, Kanada, H1T 2M4
      • Montreal, Quebec, Kanada, H3T 1E2
      • Montreal, Quebec, Kanada, H2L 1S6
      • Montreal, Quebec, Kanada, H2L 4M1
      • Quebec City, Quebec, Kanada, G1V 3M7
      • Sainte-foy, Quebec, Kanada, G1W 4R4
      • Sherbrooke, Quebec, Kanada, J1H 5N4
      • St-eustache, Quebec, Kanada, J7P 4J2
      • Trois-rivieres, Quebec, Kanada, G8Z 1Y2
  • Ruotsi
      • Boras, Ruotsi, 50182
      • Falun, Ruotsi, 79182
      • Goeteborg, Ruotsi, 41345
      • Jonkoping, Ruotsi, 551 85
      • Kalmar, Ruotsi, 39185
      • Karlskrona, Ruotsi, 37185
      • Lulea, Ruotsi, 97180
      • Malmoe, Ruotsi, 20502
      • Oskarstroem, Ruotsi, 31392
      • Skoevde, Ruotsi, 54185
      • Stockholm, Ruotsi, 18288
      • Sundsvall, Ruotsi, 85186

Osallistumiskriteerit

Tutkijat etsivät ihmisiä, jotka sopivat tiettyyn kuvaukseen, jota kutsutaan kelpoisuuskriteereiksi. Joitakin esimerkkejä näistä kriteereistä ovat henkilön yleinen terveydentila tai aiemmat hoidot.

Kelpoisuusvaatimukset

Opintokelpoiset iät

18 vuotta - 80 vuotta (Aikuinen, Vanhempi Aikuinen)

Hyväksyy terveitä vapaaehtoisia

Ei

Sukupuolet, jotka voivat opiskella

Kaikki

Kuvaus

Inclusion Criteria:

  • Adult patients, 18-80 years of age
  • Moderate to severe active rheumatoid arthritis
  • Inadequate response to a single previous or current treatment with an anti-TNF agent
  • Methotrexate for at least 12 weeks, at a stable dose over the past 4 weeks

Exclusion Criteria:

  • Previous treatment with MabThera
  • Use of an anti-TNF agent within past 8 weeks (4 in the case of etanercept)
  • Concurrent treatment with any Disease Modifying Anti-Rheumatic Drug (DMARD) other than methotrexate
  • Active infection, or history of serious or chronic infection

Opintosuunnitelma

Tässä osiossa on tietoja tutkimussuunnitelmasta, mukaan lukien kuinka tutkimus on suunniteltu ja mitä tutkimuksella mitataan.

Miten tutkimus on suunniteltu?

Suunnittelun yksityiskohdat

  • Ensisijainen käyttötarkoitus: Hoito
  • Jako: Ei käytössä
  • Inventiomalli: Yksittäinen ryhmätehtävä
  • Naamiointi: Ei mitään (avoin tarra)

Aseet ja interventiot

Osallistujaryhmä / Arm
Interventio / Hoito
Kokeellinen: Yksi käsi
Lääke: rituximab
1000 mg intravenously on Days 1 and 15

Mitä tutkimuksessa mitataan?

Ensisijaiset tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
Percentage of Participants With Adverse Events During the Initial Treatment Period - Overall Summary
Aikaikkuna: Days 1, 2, 15, and 16 and Week 48 of Initial treatment period
Percentage of participants who reported an AE or serious AE (SAE), a drug-related AE, who had an acute infusion reaction, an AE leading to study drug discontinuation, with an infection or serious infection, or who died.
Days 1, 2, 15, and 16 and Week 48 of Initial treatment period

Toissijaiset tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
Percentage of Participants With Adverse Events During the Re-Treatment Period - Overall Summary
Aikaikkuna: Days 1, 2, 15, and 16 and Week 48 of Re-treatment period
Percentage of participants who reported an AE or SAE, a drug-related AE, who had an acute infusion reaction, an AE leading to study drug discontinuation, with an infection or serious infection, or who died.
Days 1, 2, 15, and 16 and Week 48 of Re-treatment period
Percentage of Participants Meeting American College of Rheumatology (ACR) Response Criteria During the Initial Treatment Period
Aikaikkuna: Weeks 4, 12, 24, 36, and 48 of Initial treatment period
ACR20/50/70, defined as ≥20 percent (%), 50%, or 70% improvement, respectively, compared to baseline in tender joint count (TJC) and swollen joint count (SJC), and 20%/50%/70% improvement in at least 3 of 5 additional ACR core set variables: Patient Assessment of Pain; Patient's Global Assessment of Disease Activity; Physician's Global Assessment of Disease Activity; Health Assessment Questionnaire - Disability Index (HAQ-DI); and an acute phase reactant (erythrocyte sedimentation rate [ESR] or C-Reactive Protein [CRP]). If CRP was missing or not done, then ESR was used.
Weeks 4, 12, 24, 36, and 48 of Initial treatment period
Percentage of Participants With Complete Clinical Response Per ACR Criteria During the Initial Treatment Period
Aikaikkuna: Weeks 4, 12, 24, 36, and 48 of Initial treatment period
Complete clinical response was defined as having an ACR70 for at least 13 weeks.
Weeks 4, 12, 24, 36, and 48 of Initial treatment period
Percentage of Participants Meeting ACR Response Criteria During the Re-treatment Period
Aikaikkuna: Weeks 12 and 24 of Re-treatment period
ACR20/50/70, defined as ≥20%, 50%, or 70% improvement, respectively, compared to baseline in TJC and SJC, and 20%/50%/70% improvement in at least 3 of 5 additional ACR core set variables: Patient Assessment of Pain; Patient's Global Assessment of Disease Activity; Physician's Global Assessment of Disease Activity; HAQ-DI; and an acute phase reactant (ESR or CRP). If CRP was missing or not done, then ESR was used.
Weeks 12 and 24 of Re-treatment period
Percentage of Participants With Complete Clinical Response Per ACR Criteria During the Re-Treatment Period
Aikaikkuna: Weeks 12 and 24 of Re-treatment period
Complete clinical response was defined as having an ACR70 for at least 13 weeks.
Weeks 12 and 24 of Re-treatment period
Percentage of Participants Meeting European League Against Rheumatism (EULAR) Response Criteria During the Initial Treatment Period
Aikaikkuna: Weeks 4, 12, 24, 36, and 48 of Initial treatment period
The EULAR response criteria were based on the assessment of disease activity using the DAS28. The EULAR response criteria included not only change in disease activity but current disease activity. To be classified as responders, participants had to have a significant change in DAS28 and a low current disease activity. There were 4 categories of EULAR response rates: good, moderate, good/moderate, and none. The DAS28 scoring used 4 core components: SJC, TJC, Patient's Global Assessment of Disease Activity, and ESR. The DAS28 has a continuous scale ranging from 0 to 9.4. The level of disease activity was interpreted as low (DAS28 score less than or equal to [≤]3.2), moderate (DAS28 score greater than [>]3.2 but ≤5.1), or high (DAS28 score >5.1). A DAS28 score <2.6 corresponded to a state of remission according to American Rheumatism Association criteria.
Weeks 4, 12, 24, 36, and 48 of Initial treatment period
Percentage of Participants Meeting EULAR Response Criteria During the Re-Treatment Period
Aikaikkuna: Weeks 12 and 24 of Re-treatment period
The EULAR response criteria were based on the assessment of disease activity using the DAS28. The EULAR response criteria included not only change in disease activity but current disease activity. To be classified as responders, participants had to have a significant change in DAS28 and a low current disease activity. There were 4 categories of EULAR response rates: good, moderate, good/moderate, and none. The DAS28 scoring used 4 core components: SJC, TJC, Patient's Global Assessment of Disease Activity, and ESR. The DAS28 has a continuous scale ranging from 0 to 9.4. The level of disease activity was interpreted as low (DAS28 score ≤3.2), moderate (DAS28 score >3.2 but ≤5.1), or high (DAS28 score >5.1). A DAS28 score <2.6 corresponded to a state of remission according to American Rheumatism Association criteria.
Weeks 12 and 24 of Re-treatment period
Change From Baseline in DAS28 During the Initial Treatment Period
Aikaikkuna: Weeks 4, 12, 24, 36, and 48 of Initial treatment period
The DAS28 scoring used 4 core components: SJC, TJC, Patient's Global Assessment of Disease Activity, and ESR. The DAS28 has a continuous scale ranging from 0 to 9.4. The level of disease activity was interpreted as low (DAS28 score ≤3.2), moderate (DAS28 score >3.2 but ≤5.1), or high (DAS28 score >5.1). A DAS28 score <2.6 corresponded to a state of remission according to American Rheumatism Association criteria. A change of 1.2 units in DAS28 in an individual participant was considered a significant change.
Weeks 4, 12, 24, 36, and 48 of Initial treatment period
Change From Baseline in DAS28 During the Re-Treatment Period
Aikaikkuna: Weeks 12 and 24 of Re-treatment period
The DAS28 scoring used 4 core components: SJC, TJC, Patient Global Assessment of Disease Activity, and ESR. The DAS28 has a continuous scale ranging from 0 to 9.4. The level of disease activity was interpreted as low (DAS28 score ≤3.2), moderate (DAS28 score >3.2 but ≤5.1), or high (DAS28 score >5.1). A DAS28 score <2.6 corresponded to a state of remission according to American Rheumatism Association criteria. A change of 1.2 units in DAS28 in an individual participant was considered a significant change.
Weeks 12 and 24 of Re-treatment period
Change From Baseline in SJC During the Initial Treatment Period
Aikaikkuna: Weeks 4, 12, 24, 36, and 48 of Initial treatment period
Joints assessed for swelling consisted of shoulders, elbows, wrists, interphalangeal (digit 1), distal interphalangeal joints (digits 2-5), proximal interphalangeal joints (digits 2-5), metacarpophalangeal joints (digits 1-5), and knees.
Weeks 4, 12, 24, 36, and 48 of Initial treatment period
Change From Baseline in SJC During the Re-Treatment Period
Aikaikkuna: Weeks 12 and 24 of Re-treatment period
Joints assessed for swelling consisted of shoulders, elbows, wrists, interphalangeal (digit 1), distal interphalangeal joints (digits 2-5), proximal interphalangeal joints (digits 2-5), metacarpophalangeal joints (digits 1-5), and knees.
Weeks 12 and 24 of Re-treatment period
Change From Baseline in TJC During the Initial Treatment Period
Aikaikkuna: Weeks 4, 12, 24, 36, and 48 of Initial treatment period
Joints assessed for swelling consisted of shoulders, elbows, wrists, interphalangeal (digit 1), distal interphalangeal joints (digits 2-5), proximal interphalangeal joints (digits 2-5), metacarpophalangeal joints (digits 1-5), and knees.
Weeks 4, 12, 24, 36, and 48 of Initial treatment period
Change From Baseline in TJC During the Re-Treatment Period
Aikaikkuna: Weeks 12 and 24 of Re-treatment period
Joints assessed for swelling consisted of shoulders, elbows, wrists, interphalangeal (digit 1), distal interphalangeal joints (digits 2-5), proximal interphalangeal joints (digits 2-5), metacarpophalangeal joints (digits 1-5), and knees.
Weeks 12 and 24 of Re-treatment period
Change From Baseline in Physician's Global Assessment of Disease Activity During the Initial Treatment Period
Aikaikkuna: Weeks 4, 12, 24, 36, and 48 of Initial treatment period
Physician Global Assessment of Disease Activity was measured using a 100-mm visual analog scale (VAS) where the extreme left end of the line was 0 = no disease activity and the extreme right end of the line was 100 = maximum disease activity. The physician marked the line and the distance from the left edge was measured in mm.
Weeks 4, 12, 24, 36, and 48 of Initial treatment period
Change From Baseline in Physician's Global Assessment of Disease Activity During the Re-Treatment Period
Aikaikkuna: Weeks 12 and 24 of Re-treatment period
Physician Global Assessment of Disease Activity was measured using a 100-mm VAS where the extreme left end of the line was 0 = no disease activity and the extreme right end of the line was 100 = maximum disease activity. The physician marked the line and the distance from the left edge was measured in mm.
Weeks 12 and 24 of Re-treatment period
Change From Baseline in Patient Global Assessment of Disease Activity Score During the Initial Treatment Period
Aikaikkuna: Weeks 4, 12, 24, 36, and 48 of Initial treatment period
Patient Global Assessment of Disease Activity was measured using a 100-mm VAS where the extreme left end of the line was 0 = no disease activity and the extreme right end of the line was 100 = maximum disease activity. The participant was asked to marked the line and the distance from the left edge was measured in mm.
Weeks 4, 12, 24, 36, and 48 of Initial treatment period
Change From Baseline in Patient Global Assessment of Disease Activity During the Re-Treatment Period
Aikaikkuna: Weeks 12 and 24 of Re-treatment period and Week 4 after last maintenance
Patient Global Assessment of Disease Activity was measured using a 100-mm VAS where the extreme left end of the line was 0 = no disease activity and the extreme right end of the line was 100 = maximum disease activity. The participant was asked to marked the line and the distance from the left edge was measured in mm.
Weeks 12 and 24 of Re-treatment period and Week 4 after last maintenance
Change From Baseline in Patient Global Assessment of Pain During the Initial Treatment Period
Aikaikkuna: Weeks 4, 12, 24, 36, and 48 of Initial treatment period
Patient Global Assessment of Pain was measured using a 100-mm VAS where the extreme left end of the line was 0 = no pain and the extreme right end of the line was 100 = unbearable pain. The participant was asked to mark the line and the distance from the left edge was measured in mm.
Weeks 4, 12, 24, 36, and 48 of Initial treatment period
Change From Baseline in Patient Global Assessment of Pain During the Re-Treatment Period
Aikaikkuna: Weeks 12 and 24 of Re-treatment period
Patient Global Assessment of Pain was measured using a 100-mm VAS where the extreme left end of the line was 0 = no pain and the extreme right end of the line was 100 = unbearable pain. The participant was asked to mark the line and the distance from the left edge was measured in mm.
Weeks 12 and 24 of Re-treatment period
Change From Baseline HAQ-DI Score During the Initial Treatment Period
Aikaikkuna: Weeks 4, 12, 24, 36, and 48 of Initial treatment period
HAQ-DI: 20 questions, 8 categories of functioning: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and common usual activities. Participants report amount of difficulty in performing 2-3 specific subcategory items. Difficulty score is from 0 to 3 (0 = without any difficulty; 1 = with some difficulty; 2 = with much difficulty; and 3 = unable to do). The highest component score in each of the 8 categories determined the score for that category, unless aids, devices, and/or help from another person were required which = a score of 2 (unless already 2 or 3). The 8 category scores were averaged into overall HAQ-DI score ranging from 0 to 3 (0 to 1 = mild to moderate difficulty; 1 to 2 = moderate to severe disability; and 2 to 3 = severe to very severe disability). HAQ-DI not computed if > 2 categories were missing.
Weeks 4, 12, 24, 36, and 48 of Initial treatment period
Change From Baseline HAQ-DI Score During the Re-Treatment Period
Aikaikkuna: Weeks 12 and 24 of Re-treatment period
HAQ-DI: 20 questions, 8 categories of functioning: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and common usual activities. Participants report amount of difficulty in performing 2-3 specific subcategory items. Difficulty score is from 0 to 3 (0 = without any difficulty; 1 = with some difficulty; 2 = with much difficulty; and 3 = unable to do). The highest component score in each of the 8 categories determines the score for that category, unless aids, devices, and/or help from another person were required which = a score of 2 (unless already 2 or 3). The 8 category scores were averaged into overall HAQ-DI score ranging from 0 to 3 (0 to 1 = mild to moderate difficulty; 1 to 2 = moderate to severe disability; and 2 to 3 = severe to very severe disability). HAQ-DI not computed if >2 categories were missing.
Weeks 12 and 24 of Re-treatment period
Change From Baseline in ESR During the Initial Treatment Period
Aikaikkuna: Weeks 4, 12, 24, 36, and 48 of Initial treatment period
ESR was measured in mm/hour and was used to determine the acute phase response. Lower ESR values indicate reduction in disease activity; normal reference range: 0-20 mm/hr.
Weeks 4, 12, 24, 36, and 48 of Initial treatment period
Change From Baseline in ESR During the Re-Treatment Period
Aikaikkuna: Weeks 12 and 24 of Re-treatment period
ESR was measured in mm/hour and was used to determine the acute phase response. Lower ESR values indicate reduction in disease activity; normal reference range: 0-20 mm/hr.
Weeks 12 and 24 of Re-treatment period
Change From Baseline in CRP During the Initial Treatment Period
Aikaikkuna: Weeks 4, 12, 24, 36, and 48 of Initial treatment period
CRP levels were measured in milligrams/liter (mg/L) and were used to determine the acute phase response. A reduction in CRP levels is considered an improvement; normal reference range ≤10 mg/L.
Weeks 4, 12, 24, 36, and 48 of Initial treatment period
Change From Baseline CRP During the Re-Treatment Period
Aikaikkuna: Weeks 12 and 24 of Re-treatment period
CRP levels were measured in mg/L and were used to determine the acute phase response. A reduction in CRP levels is considered an improvement; normal reference range ≤10 mg/L.
Weeks 12 and 24 of Re-treatment period
Percentage of Participants With Disease Remission According to DAS28 in the Initial Treatment Period
Aikaikkuna: Weeks 4, 12, 24, 36, and 48 of Initial treatment period
The DAS28 scoring used 4 core components: SJC, TJC, Patient's Global Assessment of Disease Activity, and ESR. The DAS28 has a continuous scale ranging from 0 to 9.4. The level of disease activity was interpreted as low (DAS28 score ≤3.2), moderate (DAS28 score >3.2 but ≤5.1), or high (DAS28 score >5.1). A DAS28 score ≤2.6 corresponded to a state of remission according to American Rheumatism Association criteria.
Weeks 4, 12, 24, 36, and 48 of Initial treatment period
Percentage of Participants With Disease Remission According to DAS28 in the Re-Treatment Period
Aikaikkuna: Weeks 12 and 24 of Re-treatment period
The DAS28 scoring used 4 core components: SJC, TJC, Patient's Global Assessment of Disease Activity, and ESR. The DAS28 has a continuous scale ranging from 0 to 9.4. The level of disease activity was interpreted as low (DAS28 score ≤3.2), moderate (DAS28 score >3.2 but ≤5.1), or high (DAS28 score >5.1). A DAS28 score ≤2.6 corresponded to a state of remission according to American Rheumatism Association criteria.
Weeks 12 and 24 of Re-treatment period
Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Total Score During the Initial Treatment Period
Aikaikkuna: Weeks 4, 12, 24, 36, and 48 of Initial treatment period
Participant fatigue was evaluated using the FACIT-F scale, a 13-item questionnaire in which the participants were requested to score each item on a 5-point scale. The FACIT-F scores ranged from 0 to 52, with higher scores representing less fatigue. Score changes of 4 points or more were considered clinically meaningful. The total score was a summation of all 13 items, where 2 of the positive items (I have energy; I am able to do my usual activities) were reversed for scoring.
Weeks 4, 12, 24, 36, and 48 of Initial treatment period
Change From Baseline in FACIT-F Total Score During the Re-Treatment Period
Aikaikkuna: Weeks 12 and 24 of Re-treatment period
Participant fatigue was evaluated using the FACIT-F scale, a 13-item questionnaire in which the participants were requested to score each item on a 5-point scale. The FACIT-F scores ranged from 0 to 52, with higher scores representing less fatigue. Score changes of 4 points or more were considered clinically meaningful. The total score was a summation of all 13 items, where 2 of the positive items (I have energy; I am able to do my usual activities) were reversed for scoring.
Weeks 12 and 24 of Re-treatment period

Yhteistyökumppanit ja tutkijat

Täältä löydät tähän tutkimukseen osallistuvat ihmiset ja organisaatiot.

Sponsori

Hoffmann-La Roche

Opintojen ennätyspäivät

Nämä päivämäärät seuraavat ClinicalTrials.gov-sivustolle lähetettyjen tutkimustietueiden ja yhteenvetojen edistymistä. National Library of Medicine (NLM) tarkistaa tutkimustiedot ja raportoidut tulokset varmistaakseen, että ne täyttävät tietyt laadunvalvontastandardit, ennen kuin ne julkaistaan ​​julkisella verkkosivustolla.

Opi tärkeimmät päivämäärät

Opiskelun aloitus (Todellinen)

Tiistai 18. heinäkuuta 2006

Ensisijainen valmistuminen (Todellinen)

Torstai 12. maaliskuuta 2009

Opintojen valmistuminen (Todellinen)

Torstai 12. maaliskuuta 2009

Opintoihin ilmoittautumispäivät

Ensimmäinen lähetetty

Perjantai 7. tammikuuta 2011

Ensimmäinen toimitettu, joka täytti QC-kriteerit

Perjantai 7. tammikuuta 2011

Ensimmäinen Lähetetty (Arvio)

Maanantai 10. tammikuuta 2011

Tutkimustietojen päivitykset

Viimeisin päivitys julkaistu (Todellinen)

Tiistai 15. elokuuta 2017

Viimeisin lähetetty päivitys, joka täytti QC-kriteerit

Torstai 6. heinäkuuta 2017

Viimeksi vahvistettu

Torstai 1. kesäkuuta 2017

Lisää tietoa

Tähän tutkimukseen liittyvät termit

Muita asiaankuuluvia MeSH-ehtoja

Muut tutkimustunnusnumerot

  • ML20381

Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .

Kliiniset tutkimukset Nivelreuma

Kliiniset tutkimukset rituximab

Hae vastaavia kokeiluja

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

CROs by country

CROs in Chile

Ehdot

Harvinaiset sairaudet

Huumeiden interventiot

Ravintolisät

Sponsori / yhteistyökumppanit

Sijainnit

3
Tilaa